A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas

MLA

Monica Chanda, et al. “A Novel C-Terminal Hsp90 Inhibitor KU758 Synergizes Efficacy in Combination with BRAF or MEK Inhibitors and Targets Drug-Resistant Pathways in BRAF-Mutant Melanomas.” Melanoma Research, vol. 31, no. 3, Apr. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1e506683c54633d53faa736e76c7df38&authtype=sso&custid=ns315887.

APA

Monica Chanda, Mark S. Cohen, Nina Zhang, Ton Wang, Brian S. J. Blagg, Chitra Subramanian, Barbara N. Timmermann, Jackee N Sanchez, & Gary Shanguan. (2021). A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Melanoma Research, 31(3).

Chicago

Monica Chanda, Mark S. Cohen, Nina Zhang, Ton Wang, Brian S. J. Blagg, Chitra Subramanian, Barbara N. Timmermann, Jackee N Sanchez, and Gary Shanguan. 2021. “A Novel C-Terminal Hsp90 Inhibitor KU758 Synergizes Efficacy in Combination with BRAF or MEK Inhibitors and Targets Drug-Resistant Pathways in BRAF-Mutant Melanomas.” Melanoma Research 31 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1e506683c54633d53faa736e76c7df38&authtype=sso&custid=ns315887.